In addition, there was nosignificant difference in apoptotic rate between Ad-TRAIL- andAd-TRAIL-MRE-1-133-218-treated bladder cancer cells, suggesting no impairment ofapoptosis-inducing capacity caused by this modification (Figure 3a). This evidence concerns the gene TNFSF10 and urinary bladder cancer.